1241496-36-5Relevant academic research and scientific papers
Discovery of pyrrolidine-based β-secretase inhibitors: Lead advancement through conformational design for maintenance of ligand binding efficiency
Stachel, Shawn J.,Steele, Thomas G.,Petrocchi, Alessia,Haugabook, Sharie J.,McGaughey, Georgia,Katharine Holloway,Allison, Timothy,Munshi, Sanjeev,Zuck, Paul,Colussi, Dennis,Tugasheva, Katherine,Wolfe, Abigail,Graham, Samuel L.,Vacca, Joseph P.
, p. 240 - 244 (2012/03/10)
We have developed a novel series of pyrrolidine derived BACE-1 inhibitors. The potency of the weak initial lead structure was enhanced using library-based SAR methods. The series was then further advanced by rational design while maintaining a minimal ligand binding efficiency threshold. Ultimately, the co-crystal structure was obtained revealing that these inhibitors interacted with the enzyme in a unique fashion. In all, the potency of the series was enhanced by 4 orders of magnitude from the HTS lead with concomitant increases in physical properties needed for series advancement. The progression of these developments in a systematic fashion is described.
SPIROPYRROLIDINE BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE
-
Example 63, (2010/09/17)
The present invention is directed to spiropyrrolidine compounds of formula (I) which are inhibitors of the beta-secretase enzyme and that are useful in the treatment of diseases in which the beta-secretase enzyme is involved, such as Alzheimer's disease.
